We are seeking GPs and other healthcare professionals in Victoria, Australia to pilot a new point-of-care test to help differentiate patients with viral from bacterial acute respiratory tract infections.
We are seeking GPs and other healthcare professionals in Victoria, Australia to pilot a new point-of-care test to help differentiate patients with viral from bacterial acute respiratory tract infections.
FebriDx® is a simple 10-minute point-of-care fingerstick test that helps differentiate viral infections that may necessitate isolation, from bacterial infections that require antibiotic therapy.
Due to the COVID-19 pandemic and potential impact of the impending flu season, Lumos Diagnostics, a Planet Innovation company, is working with the Victorian Government to demonstrate the benefits and impact that the FebriDx test may deliver as an acute respiratory infection (ARI) patient triage tool in the Australian healthcare system.
The FebriDx test is CE-marked and included on the ARTG (Australian Register of Therapeutic Goods). It is commercially available in Europe, Canada, Australia and various other countries.
We are asking for GPs, emergency departments and other healthcare professionals in the state of Victoria to help improve patient triaging by participating in this free FebriDx initiative. Please register to express your interest in participating, or to receive more information.
FebriDx is a 10-minute point-of-care (POC) test that rapidly assesses the body’s host immune response to an acute respiratory infection (ARI) and helps identify viral infections that may necessitate isolation from bacterial infections that require antibiotic therapy.
By enabling a rapid diagnostic triage at the initial visit or screening stage, the FebriDx test can assist health professionals with decision-making and may thereby help:
FebriDx is an easy-to-use, all-in-one, disposable test that enables clinicians to take a fingerstick blood sample and get a rapid result, all within one hand-held device. The test simultaneously detects Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from peripheral whole blood. MxA is an intracellular protein that becomes elevated in the presence of acute viral infection and CRP is an acute-phase inflammatory protein that is elevated in the presence of clinically significant infection.
Clinical performance from two prospective multi-center US clinical trials demonstrate the FebriDx test’s high accuracy and 97-99% negative predictive value to exclude a bacterial infection.1,2
In a United Kingdom outcome study, FebriDx was shown to alter clinical management decisions in 48% of patients tested and reduced unnecessary antibiotic prescriptions by 80%3.
For more information about FebriDx, please visit the FebriDx website.